Journal article
Kawasaki disease and immunisation: A systematic review.
- Phuong LK Monash Children's Hospital, Clayton, Melbourne, Australia; Royal Children's Hospital, Parkville, Victoria, Australia.
- Bonetto C Italian Medicines Agency (AIFA), Rome, Italy.
- Buttery J Monash Children's Hospital, Clayton, Melbourne, Australia; Murdoch Childrens Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, Monash University, Clayton, Victoria, Australia.
- Pernus YB The Brighton Collaboration Foundation, Basel, Switzerland.
- Chandler R Uppsala Monitoring Centre, Uppsala, Sweden.
- Felicetti P Italian Medicines Agency (AIFA), Rome, Italy.
- Goldenthal KL Independent Consultant, Bethesda, MD, USA.
- Kucuku M Department of Vaccines Control, National Agency for Medicines and Medical Devices, Tirana, Albania.
- Monaco G Pharmacovigilance Regional Centre of Lombardy, Italy.
- Pahud B Children's Mercy Hospital, Kansas City, MO, USA.
- Shulman ST Ann & Robert H. Lurie Children's Hospital of Chicago, USA.
- Top KA Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
- Trotta F Italian Medicines Agency (AIFA), Rome, Italy.
- Ulloa-Gutierrez R Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera, San José, Costa Rica.
- Varricchio F Independent Consultant Vaccinologist, Wakefield, RI, USA.
- de Ferranti S Boston Children's Hospital, Boston, USA.
- Newburger JW Boston Children's Hospital, Boston, USA.
- Dahdah N CHU Sainte-Justine, Montreal, Canada.
- Singh S Post Graduate Institute of Medical Education and Research (PGIMER)- Chandigarh, India.
- Bonhoeffer J The Brighton Collaboration Foundation, Basel, Switzerland; University of Basel Children's Hospital, Basel, Switzerland. Electronic address: contact@brightoncollaboration.org.
- Burgner D Monash Children's Hospital, Clayton, Melbourne, Australia; Murdoch Childrens Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, Monash University, Clayton, Victoria, Australia; Department of Paediatrics, Melbourne University, Parkville, Victoria, Australia.
- 2017-03-06
Published in:
- Vaccine. - 2017
Adverse event
Case definition
Guidelines
Immunisation
Kawasaki disease
Systematic review
Humans
Immunization
Mucocutaneous Lymph Node Syndrome
Risk
Vaccination
Vaccines
English
BACKGROUND
Kawasaki disease is a complex and potentially serious condition. It has been observed in temporal relation to immunisation.
METHODS
We conducted a systematic literature review using various reference sources to review the available evidence published in the literature.
RESULTS
We identified twenty seven publications reporting a temporal association between immunisation and Kawasaki disease. We present a systematic review of data drawn from randomised controlled trials, observational studies, case series and reports, and reviews. Overall there was a lack of standardised case definitions, making data interpretation and comparability challenging.
CONCLUSIONS
Although a temporal relationship between immunisation and Kawasaki disease is suggested, evidence for an increased risk or a causal association is lacking. Implementation of a standardised Kawasaki disease case definition would increase confidence in the findings and add value to future studies of pre- or post-licensure vaccine safety studies.
Kawasaki disease is a complex and potentially serious condition. It has been observed in temporal relation to immunisation.
METHODS
We conducted a systematic literature review using various reference sources to review the available evidence published in the literature.
RESULTS
We identified twenty seven publications reporting a temporal association between immunisation and Kawasaki disease. We present a systematic review of data drawn from randomised controlled trials, observational studies, case series and reports, and reviews. Overall there was a lack of standardised case definitions, making data interpretation and comparability challenging.
CONCLUSIONS
Although a temporal relationship between immunisation and Kawasaki disease is suggested, evidence for an increased risk or a causal association is lacking. Implementation of a standardised Kawasaki disease case definition would increase confidence in the findings and add value to future studies of pre- or post-licensure vaccine safety studies.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.vaccine.2016.09.033
- PMID 28259442
- Persistent URL
- https://folia.unifr.ch/global/documents/270489
Statistics
Document views: 88
File downloads: